Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.67 |
| ▸ | EPAS1 | Q99814 | 5/20 | 0.67 |
| ▸ | NPC1 | O15118 | 4/20 | 0.65 |
| ▸ | RAB9A | P51151 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24728688 | 0.86 | HIF1A (0.68) | KMT2AHIF1AEPAS1NPC1RAB9A | |
| SCHEMBL15705708 | 0.86 | HDAC6 (0.73) | ALDH1A1KDM4E | |
| SCHEMBL10154018 | 0.84 | HDAC6 (0.71) | KMT2AALDH1A1KDM4E | |
| SCHEMBL16810264 | 0.83 | HDAC6 (0.60) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL10154345 | 0.83 | HDAC6 (0.78) | — | |
| SCHEMBL10153821 | 0.83 | ABL1 (0.59) | KMT2AHIF1AEPAS1NPC1RAB9A | |
| SCHEMBL10272436 | 0.83 | KMT2A (0.77) | KMT2AHIF1AEPAS1NPC1RAB9A | |
| SCHEMBL540760 | 0.83 | HRH3 (0.65) | KMT2AHIF1AEPAS1NPC1RAB9A | |
| SCHEMBL8027548 | 0.82 | HPGD (0.68) | KMT2AHIF1AEPAS1NPC1RAB9A | |
| SCHEMBL14045111 | 0.82 | KMT2A (0.67) | KMT2AHIF1AEPAS1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300264-A1 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | CONNOLLY PETER J | 2008-12-04 | — | — | US | disclosed |
| US-7427625-B2 | Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-09-23 | — | — | US | disclosed |
| US-20070225309-A1 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225309-A1 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | MAP3K11, MAP3K6, MAP4K2 | KMT2A 1624/4885HIF1A 1413/4885EPAS1 1253/4885 |
| US-20080300264-A1 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | MAP3K11, MAP3K6, MAP4K2 | KMT2A 1624/4885HIF1A 1413/4885EPAS1 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.